|Bid||3.5000 x 1000|
|Ask||3.7100 x 800|
|Day's Range||3.5300 - 3.7800|
|52 Week Range||1.4000 - 14.8800|
|Beta (5Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 05, 2022 - Dec 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.00|
Subscribe to Yahoo Finance Plus to view Fair Value for EPIX
Technical analysis (TA) involves the careful study of a stock's chart patterns and trends. Although this set of skills may seem daunting at first, even beginners can incorporate a few select TA methodologies into their investing strategy to great success.
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Positive Preliminary Results from Combination Therapy of EPI-7386 and Enzalutamide On October 28, 2022, ESSA Pharma Inc (NASDAQ:EPIX) announced multiple poster presentations at the 29th Annual Prostate Cancer Foundation Scientific Retreat, including an update on the Phase 1/2 Study of EPI-7386 in combination with
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in two upcoming investor conferences.